Wegovy in Europe: DACH Expansion, Clinical Impact & Investment Outlook

The European Commission has approved a higher dose of Novo Nordisk’s obesity drug Wegovy, paving the way for its launch in April, according to the Food and Drug Administration’s announcement on Thursday. The higher, 7.2-milligram dose is intended to better compete with Eli Lilly’s Zepbound, which has demonstrated greater efficacy in weight loss trials.

The approval follows positive recommendations from the European Medicines Agency (EMA), which has also broadened the indications for Wegovy to include patients with a body mass index (BMI) of 27 or higher in combination with comorbidities. This expands the potential patient pool within the European Union, as previously the drug was indicated for those with a BMI of 30 or higher.

Clinical trials of the higher dose Wegovy showed an average weight loss of 20.7% after 72 weeks, compared to approximately 15% weight loss observed with the standard 2.4-milligram dose. Novo Nordisk anticipates the increased efficacy will support regain market share lost to Zepbound.

Regulatory advancements are also resolving supply bottlenecks that previously limited Wegovy’s availability. In Germany, negotiations are underway for partial reimbursement by the public health system, potentially increasing prescriptions by 40%, according to sector estimates. Austria is conducting pilot programs in Vienna, reporting an 85% adherence rate among participants. Switzerland approved Wegovy in February, positioning it as a leading option against competitors like Saxenda.

Wegovy’s active ingredient, semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist, working by reducing appetite and regulating glucose. Phase IV studies have confirmed sustained weight loss over a year. The STEP trials, involving over 4,500 participants, demonstrated Wegovy’s superiority over placebo.

Novo Nordisk has increased production capacity by 50%, prioritizing supply to Europe amid global demand. Projections estimate Wegovy will generate €2.5 billion in European sales by the complete of 2026, a 60% increase from 2025. This growth is driven by the increasing prevalence of obesity, affecting 23% of European adults.

Recent trials, including SELECT, have shown a 20% reduction in cardiovascular risk for type 2 diabetics using Wegovy, elevating its potential beyond weight loss to preventative healthcare. Patients in Germany have reported improvements in quality of life, with 80% expressing satisfaction after six months. Austrian longitudinal studies indicate weight maintenance in 65% of users over two years, surpassing results from diet-only interventions.

Despite the positive developments, supply challenges remain a concern. Germany is implementing pharmaceutical quotas to ensure equitable access, whereas Austria is utilizing strategic reserves. Switzerland has negotiated direct contracts with Novo Nordisk to guarantee uninterrupted supply. The company is also exploring oral formulations to reduce reliance on injections.

Novo Nordisk’s stock (DK0060534915) is currently trading with a price-to-earnings ratio of 35, reflecting investor confidence in the drug’s growth potential. Analysts at DWS and Vontobel recommend a ‘buy’ rating with a target price of €120. The company is investing €500 million in localized marketing efforts.

The EMA is scheduled for annual safety reviews of Wegovy and Novo Nordisk is investing in blockchain traceability to ensure supply chain integrity. Authorities are actively combating counterfeit products appearing on the black market, with monthly seizures of illegal batches reported across the DACH region.